Other Income (Expense), Net
|
| | | | | | | | | | | |
| Years Ended March 31, |
(In millions) | 2013 | 2012 | 2011 |
Interest income | $ | 22 |
| | $ | 19 |
| | $ | 18 |
|
Equity in earnings (loss), net (1) | 3 |
| | 9 |
| | (6 | ) |
Reimbursement of post-acquisition interest expense | — |
| | — |
| | 16 |
|
Impairment of an investment | — |
| | (6 | ) | | — |
|
Other, net | 10 |
| | (1 | ) | | 8 |
|
Total | $ | 35 |
| | $ | 21 |
| | $ | 36 |
|
| |
(1) | Primarily recorded within our Distribution Solutions segment. |
In 2011, other income (expense), net included a credit of $16 million representing the reimbursement of post-acquisition interest expense by the former shareholders of US Oncology, which is recorded in Corporate.
We evaluate our investments for impairment when events or changes in circumstances indicate that the carrying values of such investments may have experienced an other-than-temporary decline in value.
